The Motley Fool··Jonathan PoncianoAvidity Partners Bets $9M on Newly Public Cancer Therapy Startup Aktis Oncology
Avidity Partners deployed $9.1M into newly public biotech Aktis Oncology, backing miniprotein-based cancer radiopharmaceuticals with $538.5M cash runway.
AKTSIPOclinical-stage